Pharma Sector

Recommendation: Buy; Target price: ₹ 1060

The price band for the ₹525.14 Crore offer has been set at ₹177 – ₹186 per equity share.

Sheetal Agarwal of IIFL chats with the management on the eve of the IPO.

Investors with very high risk appetite and want to invest for 5 to 7 years to diversify their portfolio in healthcare companies stocks should invest in DSP Nifty Healthcare ETF.

GLS has seen a 52% increase in its share price over the past three months, reaching a 52-week high of Rs 595

The company announced plans to consider a fund-raise in an upcoming board meeting scheduled for July 11.

According to Lupin's annual report for 2022, its API arm contributed approximately 6 % to the company's total revenue

LordsMed's goal of facilitating early-stage healthcare intervention and generating Rs75 crore in revenue in six months includes expanding the distribution network.

Dr Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.

By February 15, the company will invest upto Rs175 crore by subscribing to shares representing a 39.4% stake in the startup.